6th April, 2026, Mumbai: One of India’s leading consulting firms, VERTICES PARTNERS, recently advised a US-headquartered full-suite life sciences advisory firm – Red Nucleus for its acquisition of 100% stake in UK-based biopharmaceutical research company Bridge Medical Consulting Limited. The acquisition gives Red Nucleus an indirect acquisition of Bridge Medical Consulting Limited’s Indian subsidiary, Bridge Medical Consulting Private Limited.
The thoughtfully driven acquisition is in line with Red Nucleus’ expansion vision to advise global clientele and support biopharma companies. Leveraging Bridge Medical Consulting’s expertise, Red Nucleus will further strengthen its ability to help clients demonstrate the clinical and economic value of therapies in an environment that is increasingly convoluted on the regulatory and reimbursement fronts.
VERTICES PARTNERS led the transaction wherein Partners Rajat Agarwal and Vikrant Anand, along with Principal Associate Varun Kaka, Senior Associate Amit Shekhar, and Associate Hemant Srivastava, played a significant role in helping Red Nucleus navigate the intricacies of the acquisition processes. Founder and Managing Partner Vinayak Burman provided strategic direction throughout the process.
Kirkland & Ellis LLP and HCR Law were the legal advisors to Red Nucleus in the United Kingdom, while Birketts LLP represented Bridge Medical Consulting Limited.
The acquisition showcases Red Nucleus’ continued focus on building a globally integrated platform to meet the continually growing needs of the biopharmaceutical industry.
